[go: up one dir, main page]

SMT201500155B - Nuovi derivati di (eterociclo-piperidina condensata)-(piperazinil)-1-alcanone o di (eterociclo-pirrolidina condensata)-(piperazinil)-1-alcanone e lorouso come inibitori di P75 - Google Patents

Nuovi derivati di (eterociclo-piperidina condensata)-(piperazinil)-1-alcanone o di (eterociclo-pirrolidina condensata)-(piperazinil)-1-alcanone e lorouso come inibitori di P75

Info

Publication number
SMT201500155B
SMT201500155B SM201500155T SM201500155T SMT201500155B SM T201500155 B SMT201500155 B SM T201500155B SM 201500155 T SM201500155 T SM 201500155T SM 201500155 T SM201500155 T SM 201500155T SM T201500155 B SMT201500155 B SM T201500155B
Authority
SM
San Marino
Prior art keywords
alcanone
piperazinyl
condensed heterocycle
pyrrolidine
piperidine
Prior art date
Application number
SM201500155T
Other languages
English (en)
Italian (it)
Inventor
Marco Baroni
Francoise Bono
Sandrine Delbary-Gossart
Valentina Vercesi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SMT201500155B publication Critical patent/SMT201500155B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/12—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
    • C08G61/122—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides
    • C08G61/123—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides derived from five-membered heterocyclic compounds
    • C08G61/126—Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule derived from five- or six-membered heterocyclic compounds, other than imides derived from five-membered heterocyclic compounds with a five-membered ring containing one sulfur atom in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SM201500155T 2009-12-14 2015-07-01 Nuovi derivati di (eterociclo-piperidina condensata)-(piperazinil)-1-alcanone o di (eterociclo-pirrolidina condensata)-(piperazinil)-1-alcanone e lorouso come inibitori di P75 SMT201500155B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0906023A FR2953839A1 (fr) 2009-12-14 2009-12-14 Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
PCT/FR2010/052685 WO2011080444A1 (fr) 2009-12-14 2010-12-13 NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75

Publications (1)

Publication Number Publication Date
SMT201500155B true SMT201500155B (it) 2015-09-07

Family

ID=42246205

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500155T SMT201500155B (it) 2009-12-14 2015-07-01 Nuovi derivati di (eterociclo-piperidina condensata)-(piperazinil)-1-alcanone o di (eterociclo-pirrolidina condensata)-(piperazinil)-1-alcanone e lorouso come inibitori di P75

Country Status (41)

Country Link
US (2) US8580790B2 (xx)
EP (1) EP2513108B1 (xx)
JP (1) JP5735979B2 (xx)
KR (1) KR101724386B1 (xx)
CN (1) CN102741248B (xx)
AR (1) AR079441A1 (xx)
AU (1) AU2010338110B2 (xx)
BR (1) BR112012014208A8 (xx)
CA (1) CA2784152C (xx)
CL (1) CL2012001579A1 (xx)
CO (1) CO6501122A2 (xx)
CR (1) CR20120314A (xx)
CY (1) CY1116542T1 (xx)
DK (1) DK2513108T3 (xx)
DO (1) DOP2012000156A (xx)
EA (1) EA021985B1 (xx)
EC (1) ECSP12011970A (xx)
ES (1) ES2541366T3 (xx)
FR (1) FR2953839A1 (xx)
GT (1) GT201200177A (xx)
HN (1) HN2012001262A (xx)
HR (1) HRP20150707T1 (xx)
HU (1) HUE024988T2 (xx)
IL (1) IL220376A (xx)
MA (1) MA33915B1 (xx)
ME (1) ME02164B (xx)
MX (1) MX2012006865A (xx)
NI (1) NI201200104A (xx)
NZ (1) NZ600593A (xx)
PE (1) PE20121507A1 (xx)
PH (1) PH12012501169A1 (xx)
PL (1) PL2513108T3 (xx)
PT (1) PT2513108E (xx)
RS (1) RS54068B1 (xx)
SG (1) SG181709A1 (xx)
SI (1) SI2513108T1 (xx)
SM (1) SMT201500155B (xx)
TN (1) TN2012000285A1 (xx)
TW (1) TW201130850A (xx)
UY (1) UY33105A (xx)
WO (1) WO2011080444A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
CN107245074B (zh) * 2017-06-20 2019-04-09 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法
EP3749667A1 (en) 2018-02-05 2020-12-16 Alkermes, Inc. Compounds for the treatment of pain
EP4105206A4 (en) * 2020-01-13 2024-08-14 Aptabio Therapeutics Inc. NOVEL PYRAZOLE DERIVATIVE
WO2025117677A1 (en) * 2023-11-29 2025-06-05 Actio Biosciences, Inc. Heterocyclic compounds useful as kcnt1 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457869A1 (fr) * 1979-05-09 1980-12-26 Sanofi Sa Derives de thieno(2',3'; 4,5) pyrido (1,2-a) pyrazine, leur procede de preparation et leur application therapeutique
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
WO1998017278A1 (en) 1996-10-21 1998-04-30 Allelix Biopharmaceuticals Inc. Neurotrophin antagonist compositions
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
GB9905010D0 (en) * 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU4198400A (en) 1999-04-06 2000-10-23 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
DE60103761D1 (de) * 2000-06-29 2004-07-15 Lundbeck As Kopenhagen Koebenh Indolderivate zum gebrauch in der behandlung von zns-störungen
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
TW200413351A (en) * 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
FR2862968B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
WO2005070930A2 (en) * 2004-01-23 2005-08-04 Chiron Corporation Tetrahydrocarboline compounds as anticancer agents
EP1797054A2 (en) * 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
US20110071180A1 (en) * 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
CN101284838B (zh) * 2008-06-06 2011-05-04 天津药物研究院 含噻吩并吡啶的哌嗪类衍生物、其制备方法和用途
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75

Also Published As

Publication number Publication date
US8580790B2 (en) 2013-11-12
ME02164B (me) 2015-10-20
KR20140015156A (ko) 2014-02-06
CN102741248A (zh) 2012-10-17
EP2513108A1 (fr) 2012-10-24
NI201200104A (es) 2012-08-21
BR112012014208A2 (pt) 2017-08-08
JP2013513649A (ja) 2013-04-22
NZ600593A (en) 2014-10-31
ECSP12011970A (es) 2012-07-31
HUE024988T2 (hu) 2016-01-28
CA2784152C (fr) 2019-04-16
WO2011080444A1 (fr) 2011-07-07
AR079441A1 (es) 2012-01-25
AU2010338110A1 (en) 2012-07-05
BR112012014208A8 (pt) 2017-12-26
AU2010338110B2 (en) 2015-10-29
FR2953839A1 (fr) 2011-06-17
US20140038946A1 (en) 2014-02-06
CL2012001579A1 (es) 2012-10-12
EA201290504A1 (ru) 2013-01-30
SI2513108T1 (sl) 2015-08-31
EA021985B1 (ru) 2015-10-30
MX2012006865A (es) 2012-06-27
CY1116542T1 (el) 2017-03-15
PL2513108T3 (pl) 2015-09-30
HN2012001262A (es) 2015-07-13
DOP2012000156A (es) 2012-09-15
CO6501122A2 (es) 2012-08-15
ES2541366T3 (es) 2015-07-17
PT2513108E (pt) 2015-08-21
DK2513108T3 (en) 2015-07-06
US20120245149A1 (en) 2012-09-27
SG181709A1 (en) 2012-07-30
KR101724386B1 (ko) 2017-04-07
TN2012000285A1 (fr) 2013-12-12
CR20120314A (es) 2012-07-12
GT201200177A (es) 2013-11-07
JP5735979B2 (ja) 2015-06-17
EP2513108B1 (fr) 2015-04-01
MA33915B1 (fr) 2013-01-02
US8957211B2 (en) 2015-02-17
IL220376A (en) 2016-05-31
UY33105A (es) 2011-07-29
CA2784152A1 (fr) 2011-07-07
RS54068B1 (sr) 2015-10-30
HK1175783A1 (en) 2013-07-12
CN102741248B (zh) 2016-01-20
PE20121507A1 (es) 2012-11-24
TW201130850A (en) 2011-09-16
IL220376A0 (en) 2012-08-30
PH12012501169A1 (en) 2012-10-29
HRP20150707T1 (hr) 2015-08-14

Similar Documents

Publication Publication Date Title
CY2019014I1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
SMT201500155B (it) Nuovi derivati di (eterociclo-piperidina condensata)-(piperazinil)-1-alcanone o di (eterociclo-pirrolidina condensata)-(piperazinil)-1-alcanone e lorouso come inibitori di P75
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
SMT201300114T1 (it) Derivati di piridazina come inibitori di smo
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
BRPI0911332A2 (pt) composições e uso de inibidores de epas1
EP2533638A4 (en) NEW INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE
UY33159A (es) Compuestos y métodos para la modulación de quinasa e indicaciones de la misma
EP2421867A4 (en) PIPERIDINIC INHIBITORS OF JANUS KINASE 3
SMT201600085B (it) Piperidin-4-il azetidin derivati come inibitori di jak1
SMT201400114B (it) Derivati di 2-arilimidazolo come inibitori dell'enzima pde10a
PT2414517T (pt) Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
SMT201400101B (it) Derivati deuterati di isoindolina-1,3-dione come inibitori di pde4 e tnf-alfa
EP3130583C0 (en) KYNURENINE-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
SMT201400009B (it) Derivati eteroaromatici di ariltriazolo come inibitori dell'enzima pde 10A
BR112014001991A2 (pt) certos inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso dos mesmos
SMT201400158B (it) Derivati eteroaromatici di fenilimidazolo come inibitori dell'enzima pde10a
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
ATE502944T1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
PL2427193T3 (pl) Zastosowanie inhibitorów pde7 do leczenia zaburzeń ruchu
HRP20180748T1 (hr) Postupak i mješavina za obradu metalnih površina
SMT201400084B (it) Nuovi derivati di 6-(osso-1,6diiro-pirimidin-2-il)-ammide, loro preparazione e loro uso farmaceuticocome inibitori di fosforilazione di akt
SMT201300067B (it) Applicazioni terapeutiche di derivati di chinazolindione
BRPI0919977A2 (pt) Derivados de 7-hidróxi-benzoimidazol-4-il-metanona e inibidores de pbk contendo os mesmos